The neuropeptide Y (NPY) receptors are abundant in a range of tumours hence are a molecular target for tumour imaging and therapy, particularly by the use of radiolabelled molecules. NG-Substituted derivatives of the NPY receptor antagonist, BIBP3226, were prepared aiming to improve its current usability and to incorporate a positron-emitting radioisotope for development in positron emission tomography (PET) radiopharmaceuticals. The BIBP3226 derivatives were prepared in seven steps while retaining the critically important amino acid chirality. The acyl derivative retained acceptable ligand binding, however the sulfonyl derivatives lost almost all binding affinity.
神经肽 Y(NPY)受体在多种肿瘤中含量丰富,因此是肿瘤成像和治疗的分子靶点,尤其是通过使用放射性标记分子。我们制备了 NPY 受体拮抗剂 BIBP3226 的 NG 取代衍生物,旨在改善其当前的可用性,并将正电子发射放射性同位素用于正电子发射断层扫描(PET)放射性药物的开发。BIBP3226 衍生物的制备分为七个步骤,同时保留了至关重要的氨基酸手性。酰基衍生物保留了可接受的配体结合力,而磺酰衍生物则几乎完全丧失了结合亲和力。